Ovid Therapeutics (OVID) Stock Price, News & Analysis

Company Overview

Ovid Therapeutics Inc. is a clinical‐stage biopharmaceutical company dedicated to developing therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, Ovid applies a precision medicine approach to address serious conditions with high unmet need, focusing primarily on pediatric and adult patients affected by developmental and epileptic encephalopathies and other central nervous system (CNS) diseases.

The company’s lead product, Ztalmy (fenfluramine) oral solution, received U.S. Food and Drug Administration approval for the treatment of seizures associated with Dravet syndrome and Lennox‐Gastaut syndrome. Ztalmy represents the first FDA‐approved therapy in its class for these indications and is supported by Phase 3 clinical data demonstrating significant reductions in seizure frequency. In addition to commercialization activities, Ovid is advancing OV935, a negative allosteric modulator of AMPA receptors in clinical development for fragile X syndrome and autism spectrum disorder, along with earlier‐stage programs targeting other rare neurologic and neurodevelopmental disorders.

Ovid Therapeutics serves patients and healthcare providers across the United States and has established strategic partnerships to support commercialization and further development in Europe and other international markets. The company collaborates with global biopharma partners to leverage regulatory expertise and distribution networks, ensuring broader access to its approved and investigational medicines. This collaborative model underpins Ovid’s goal of expanding treatment options for underserved patient populations worldwide.

Leadership at Ovid combines deep experience in neuroscience drug development with a commitment to rare disease research. Jeremy M. Levin, the company’s Chairman and Chief Executive Officer, brings more than 30 years of biopharma leadership, having held executive roles at Teva, Biogen and other global healthcare firms. Supporting the management team are seasoned professionals in clinical development, regulatory affairs and commercial operations, all aligned behind Ovid’s mission to bring innovative therapies to patients with serious neurological conditions.

Key Stats

• Today's Range: $0.39 to $0.44
• 50-Day Range: $0.28 to $0.44
• 52-Week Range: $0.24 to $1.47
• Volume: 434,052 shs
• Average Volume: 448,682 shs
• Market Capitalization: $29.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.13
• Consensus Rating: Buy

Ovid Therapeutics Stock Analysis - MarketRank™

Ovid Therapeutics scored higher than 85% of companies evaluated by MarketBeat, and ranked 157th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Ovid Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Ovid Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Ovid Therapeutics are expected to decrease in the coming year, from ($0.40) to ($0.64) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ovid Therapeutics is -1.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ovid Therapeutics is -1.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Ovid Therapeutics has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.20% of the float of Ovid Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Ovid Therapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ovid Therapeutics has recently increased by 50.60%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ovid Therapeutics does not currently pay a dividend.

Dividend Growth

Ovid Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.85

Percentage of Shares Shorted

4.20% of the float of Ovid Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Ovid Therapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ovid Therapeutics has recently increased by 50.60%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for Ovid Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for OVID on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

3 people have added Ovid Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Ovid Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.10% of the stock of Ovid Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

72.24% of the stock of Ovid Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OVID Stock Analysis - Frequently Asked Questions

How have OVID shares performed this year?

Ovid Therapeutics' stock was trading at $0.9337 on January 1st, 2025. Since then, OVID shares have decreased by 56.1% and is now trading at $0.41.

How were Ovid Therapeutics' earnings last quarter?

Ovid Therapeutics (NASDAQ:OVID) issued its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.14). The business had revenue of $0.13 million for the quarter, compared to analysts' expectations of $0.03 million. Ovid Therapeutics had a negative trailing twelve-month return on equity of 34.17% and a negative net margin of 4,562.23%.

When did Ovid Therapeutics IPO?

Ovid Therapeutics (OVID) raised $80 million in an initial public offering (IPO) on Friday, May 5th 2017. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

Who are Ovid Therapeutics' major shareholders?

Ovid Therapeutics' top institutional shareholders include Assenagon Asset Management S.A. (0.61%). Insiders that own company stock include Jeremy M Levin, Margaret A Alexander and Jason Tardio.
View institutional ownership trends.

How do I buy shares of Ovid Therapeutics?

Shares of OVID stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ovid Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ovid Therapeutics investors own include Plug Power (PLUG), Alamos Gold (AGI), FuelCell Energy (FCEL), KALA BIO (KALA), Lipocine (LPCN), Fortress Biotech (FBIO) and Workhorse Group (WKHS).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/11/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:OVID
• CIK: 1636651
• Web: www.ovidrx.com
• Phone: (646) 661-7661
• Fax: N/A
• Employees: 60
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Ovid Therapeutics: $3.13
• High Price Target: $4.00
• Low Price Target: $1.50
• Potential Upside/Downside: +645.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.35)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.43 million
• Net Margins: -4,562.23%
• Pretax Margin: -4,557.30%
• Return on Equity: -34.17%
• Return on Assets: -25.34%

Debt

• Debt-to-Equity Ratio: 0.22
• Current Ratio: 4.93
• Quick Ratio: 4.93

Sales & Book Value

• Annual Sales: $570 thousand
• Price / Sales: 52.27
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.96 per share
• Price / Book: 0.44

Miscellaneous

• Outstanding Shares: 71,110,000
• Free Float: 61,795,000
• Market Cap: $29.80 million
• Optionable: Optionable
• Beta: 0.13